US biotech major Biogen (Nasdaq: BIIB) opened the large-cap neuroscience earnings run with second-quarter revenue of $2.74 ...

UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty ...

ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...

US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug ...

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) ...

US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...

US biotech Outlook Therapeutics revealed that the US Food and Drug Administration (FDA) has approved Lytenava ...

Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from ...

Among significant news last week, Halozyme Therapeutics struck a license agreement for its INCA033989 with fellow USA-based ...

Shares in US biotech Replimune (Nasdaq: REPL) slumped around a third on Tuesday after US Food and Drug Administration (FDA) reviewers issued a harsh assessment of the company's latest bid to win ...

Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...

UK-based Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA ...